Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Dec;72(6):1547–1550. doi: 10.1038/bjc.1995.545

Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV.

M Bakker 1, H J Groen 1, E F Smit 1, J Smeets 1, M Riggi 1, P E Postmus 1
PMCID: PMC2034068  PMID: 8519675

Abstract

The aim of the study was to determine the maximum tolerated dose (MTD) for the combination of high-dose epirubicin and vinorelbine in chemotherapy-naive patients with inoperable non-small-cell lung cancer (NSCLC). Twenty-one patients with stage IIIB and IV NSCLC were treated in a single-centre study with escalating doses of epirubicin and vinorelbine given on an outpatient basis. The first dose level comprised epirubicin 100 mg m-2 on day 1 and vinorelbine 20 mg m-2 (days 1 and 8) given intravenously every 3 weeks. Escalating doses for epirubicin and vinorelbine were respectively 120 (day 1) and 20 (days 1 and 8), 120 (day 1) and 25 (days 1 and 8) and 135 (day 1) and 25 (days 1 and 8) mg m-2. Inclusion criteria were age < or = 75 years, ECOG performance score < or = 2 and normal renal, hepatic and bone marrow functions. Dose-limiting toxicities were thrombocytopenia grade II and neutropenia grade III on day 8, febrile neutropenia, and neutropenia lasting > 7 days. No dose-limiting toxicity (DLT) was observed at the first dose level; at the 135/25 mg m-2 dose level three out of six patients had a DLT which was considered as unacceptable. The only non-haematological toxicity reaching grade III was nausea/vomiting. One patient showed cardiac toxicity. No neurotoxicity and no treatment-related deaths were seen. The maximum tolerated dose of epirubicin and vinorelbine is 135 mg m-2 (day 1) and 25 mg m-2 (days 1 and 8) respectively, causing mainly haematological toxicity. The recommended dose of epirubicin and vinorelbine for phase II studies is found to be 120 mg m-2 and 20 mg m-2 respectively.

Full text

PDF
1547

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Feld R., Wierzbicki R., Walde P. L., Shepherd F. A., Evans W. K., Gupta S., Shannon P., Lassus M. Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer. J Clin Oncol. 1992 Feb;10(2):297–303. doi: 10.1200/JCO.1992.10.2.297. [DOI] [PubMed] [Google Scholar]
  2. Gridelli C., De Placido S., Pepe R., Incoronato P., Airoma G., Rossi A., Palazzolo G., Bianco A. R. Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer. Eur J Cancer. 1993;29A(12):1729–1731. doi: 10.1016/0959-8049(93)90114-u. [DOI] [PubMed] [Google Scholar]
  3. Grilli R., Oxman A. D., Julian J. A. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol. 1993 Oct;11(10):1866–1872. doi: 10.1200/JCO.1993.11.10.1866. [DOI] [PubMed] [Google Scholar]
  4. Krikorian A., Breillout F. Vinorelbine (Navelbine). A new semisynthetic vinca alkaloid. Onkologie. 1991 Feb;14(1):7–12. doi: 10.1159/000216938. [DOI] [PubMed] [Google Scholar]
  5. Launchbury A. P., Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev. 1993 Jul;19(3):197–228. doi: 10.1016/0305-7372(93)90036-q. [DOI] [PubMed] [Google Scholar]
  6. Le Chevalier T., Brisgand D., Douillard J. Y., Pujol J. L., Alberola V., Monnier A., Riviere A., Lianes P., Chomy P., Cigolari S. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994 Feb;12(2):360–367. doi: 10.1200/JCO.1994.12.2.360. [DOI] [PubMed] [Google Scholar]
  7. Lilenbaum R. C., Green M. R. Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol. 1993 Jul;11(7):1391–1402. doi: 10.1200/JCO.1993.11.7.1391. [DOI] [PubMed] [Google Scholar]
  8. Martoni A., Melotti B., Guaraldi M., Pannuti F. Activity of high-dose epirubicin in advanced non-small cell lung cancer. Eur J Cancer. 1991;27(10):1231–1234. doi: 10.1016/0277-5379(91)90087-t. [DOI] [PubMed] [Google Scholar]
  9. Nielsen D., Jensen J. B., Dombernowsky P., Munck O., Fogh J., Brynjolf I., Havsteen H., Hansen M. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990 Nov;8(11):1806–1810. doi: 10.1200/JCO.1990.8.11.1806. [DOI] [PubMed] [Google Scholar]
  10. Plosker G. L., Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs. 1993 May;45(5):788–856. doi: 10.2165/00003495-199345050-00011. [DOI] [PubMed] [Google Scholar]
  11. Smit E. F., Berendsen H. H., Piers D. A., Smeets J., Riva A., Postmus P. E. A phase II study of high dose epirubicin in unresectable non small cell lung cancer. Br J Cancer. 1992 Mar;65(3):405–408. doi: 10.1038/bjc.1992.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Souquet P. J., Chauvin F., Boissel J. P., Cellerino R., Cormier Y., Ganz P. A., Kaasa S., Pater J. L., Quoix E., Rapp E. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993 Jul 3;342(8862):19–21. doi: 10.1016/0140-6736(93)91882-m. [DOI] [PubMed] [Google Scholar]
  13. Torti F. M., Bristow M. M., Lum B. L., Carter S. K., Howes A. E., Aston D. A., Brown B. W., Jr, Hannigan J. F., Jr, Meyers F. J., Mitchell E. P. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res. 1986 Jul;46(7):3722–3727. [PubMed] [Google Scholar]
  14. Wils J., Utama I., Sala L., Smeets J., Riva A. Phase II study of high-dose epirubicin in non-small cell lung cancer. Eur J Cancer. 1990;26(11-12):1140–1141. doi: 10.1016/0277-5379(90)90271-t. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES